Related Experiment Video

Updated: Dec 29, 2025

Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

6.2K

Inotropic and lusitropic abnormalities in the genesis of heart failure

V E Smith, A M Katz

    European Heart Journal
    |January 1, 1983
    PubMed

    Insights

    Understanding heart contraction (inotropic) and relaxation (lusitropic) is crucial for diagnosing and treating heart failure. New technologies and drugs highlight the importance of these two systems in cardiac function.

    Area of Science:

    • Cardiology
    • Physiology

    Background:

    • Cardiac function relies on two key systems: inotropic (contraction/emptying) and lusitropic (relaxation/filling).
    • Heart failure symptoms can arise from dysfunctions in either or both of these systems.

    Purpose of the Study:

    • To emphasize the necessity of understanding inotropic and lusitropic roles in heart failure.
    • To correlate technological advancements with clinical understanding of cardiac function.

    Main Methods:

    • Review of cardiac pumping mechanisms.
    • Consideration of technological advances in patient evaluation (e.g., ventricular volume measurements).
    • Analysis of novel pharmacologic agents affecting myocardial properties.

    Main Results:

    • Abnormalities in either inotropic or lusitropic function can precipitate heart failure.
    • Technological advancements provide new insights into ventricular dynamics.
    • New drugs offer targeted modulation of cardiac contractile and relaxation properties.

    Conclusions:

    • A comprehensive understanding of both inotropic and lusitropic mechanisms is essential for managing heart failure.
    • Integrating advanced diagnostics and therapeutics is key to addressing the clinical syndrome of heart failure.

    More Related Videos

    Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

    Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

    Published on: October 3, 2019

    11.6K
    Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure09:37

    Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

    Published on: December 2, 2014

    28.5K

    Related Concept Videos

    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    603
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    615
    Mitral Regurgitation I: Introduction01:20

    Mitral Regurgitation I: Introduction

    Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
    312
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    1.1K
    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    2.6K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    842